IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Get Rating) gapped up prior to trading on Wednesday . The stock had previously closed at $21.90, but opened at $23.00. IDEAYA Biosciences shares last traded at $22.00, with a volume of 120,179 shares.
Analyst Upgrades and Downgrades
A number of analysts recently commented on IDYA shares. Stifel Nicolaus raised IDEAYA Biosciences from a “hold” rating to a “buy” rating and increased their price target for the company from $18.00 to $24.00 in a research report on Monday, April 24th. Oppenheimer raised their price objective on shares of IDEAYA Biosciences from $26.00 to $30.00 in a report on Monday, April 24th. The Goldman Sachs Group began coverage on shares of IDEAYA Biosciences in a report on Wednesday. They set a “buy” rating and a $32.00 price objective for the company. Guggenheim raised their price objective on shares of IDEAYA Biosciences from $32.00 to $40.00 in a report on Monday, April 24th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $25.00 price objective on shares of IDEAYA Biosciences in a report on Wednesday, March 8th. Nine analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $29.40.
IDEAYA Biosciences Price Performance
The business’s 50-day moving average price is $17.24 and its 200 day moving average price is $17.28.
Institutional Inflows and Outflows
Several large investors have recently made changes to their positions in IDYA. Ameriprise Financial Inc. increased its stake in shares of IDEAYA Biosciences by 5.6% in the first quarter. Ameriprise Financial Inc. now owns 433,682 shares of the company’s stock worth $5,954,000 after buying an additional 23,112 shares during the period. JPMorgan Chase & Co. increased its position in shares of IDEAYA Biosciences by 30.1% during the 1st quarter. JPMorgan Chase & Co. now owns 36,423 shares of the company’s stock valued at $500,000 after purchasing an additional 8,434 shares during the last quarter. Jane Street Group LLC increased its holdings in IDEAYA Biosciences by 361.7% in the 1st quarter. Jane Street Group LLC now owns 63,182 shares of the company’s stock worth $867,000 after acquiring an additional 49,496 shares in the last quarter. Geode Capital Management LLC increased its holdings in IDEAYA Biosciences by 6.7% in the 1st quarter. Geode Capital Management LLC now owns 859,934 shares of the company’s stock worth $11,807,000 after acquiring an additional 54,033 shares in the last quarter. Finally, BVF Inc. IL boosted its stake in IDEAYA Biosciences by 11.3% in the 1st quarter. BVF Inc. IL now owns 2,455,089 shares of the company’s stock worth $33,708,000 after purchasing an additional 250,000 shares during the period. 94.20% of the stock is owned by hedge funds and other institutional investors.
IDEAYA Biosciences Company Profile
IDEAYA Biosciences, Inc engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations.
- Get a free copy of the StockNews.com research report on IDEAYA Biosciences (IDYA)
- Ralph Lauren’s Styled Dividend Is Still In Season
- Dollar Tree Falls As Theft Cuts Into Bottom Line
- Best Buy’s Comeback Is Still At Play, Earnings Call For Patience
- e.l.f. Beauty Has Giant Quarter, Shares Hit New High
- If You Can Only Pick One Stock For The Rest Of 2023, Pick Nvidia
Receive News & Ratings for IDEAYA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEAYA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.